Meeting Coverage

The following is a summary of “Baseline Data and Measurement Instruments Reported in Observational...

Several studies were presented at the 2024 Crohn’s & Colitis Congress, covering the impacts on IBD of malnutrition, dietary supplements, and various diets.

A recent study and meta-analysis revealed that inflammatory bowel disease (IBD) is associated with...

A study found that preoperative exclusive enteral nutrition (EEN) in patients with Crohn’s...

Investigators concluded that AI-powered “vascular healing” analysis in UC pinpointed patients...

Patient-reported outcomes on HRQOL in psoriasis are limited and require additional validation to properly assess individuals with the condition.

Research from ASH 2023 showed standard treatment options lack efficacy for patients who are positive for the TP53 mutation with AML.

A retrospective study on advanced therapy for Inflammatory Bowel Disease (IBD) found minimal new...

A recent study found that long-term use of recombinant zoster vaccine (RZV) was associated with a...

At Maui Derm Hawaii, Joel Gelfand, MD, MSCE, presented as part of “Challenging Cases in Psoriasis.” He published 2 related papers recently, which we summarize.

Bruce Strober, MD, PhD, published a paper recently in JAMA Dermatol focusing on disease burden measurements of meaning to patients with psoriasis.

At Maui Derm Hawaii, Andrew Blauvelt, MD, MBA, presented as part of “Psoriasis Update: 2024.” Here, we summarize a paper he published in this area of study.

At Maui Derm Hawaii, held January 22-26, 2024, Linda Stein-Gold, MD, presented as part of “Challenging Cases in Psoriasis.”

Social determinants of health influenced the achievement of textbook oncological outcomes and overall survival in non-small cell lung cancer.

Lymphovascular invasion is an independent predictor for shorter recurrence-free survival for patients with stage I NSCLC.

Investigators concluded that pre-surgery nutrition support may cut hospital stays for  patients...

Researchers concluded that vedolizumab (vedo) gut-specific targeting spared passive immunity in...